CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the founder and principal of Walser Wealth Management, told Schwab Network ...

Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the founder and principal of Walser Wealth Management, told Schwab Network ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 or 3 fibrosis.

The deal, announced in March and set to close in the second quarter, marks the Swiss pharmaceutical company’s latest bid to ...

By Rebecca Robbins and Gina Kolata Encouraging ... which sells its product as Zepbound for obesity and Mounjaro for diabetes, and Novo Nordisk, which sells its medicine as Wegovy for obesity ...

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...